An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

BACKGROUND: This study aimed to develop a vaccine that targets mutation-derived neoantigen in Chinese non-small-cell lung cancer (NSCLC). METHODS: A cohort of 1862 Chinese NSCLC patients who underwent targeted sequencing with a 1021-gene panel was investigated. HLA typing was done using OptiType v1....

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jing, Liu, Jun, Hao, Shi-guang, Lan, Bin, Zheng, Xiao-bin, Xiong, Jia-ni, Zhang, Ying-qian, Gao, Xuan, Chen, Chuan-ben, Chen, Ling, Huang, Yu-fang, Luo, Hong, Yi, Yu-ting, Yi, Xin, Lu, Jian-ping, Zheng, Xiong-wei, Chen, Gang, Wang, Xue-feng, Chen, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727402/
https://www.ncbi.nlm.nih.gov/pubmed/36505399
http://dx.doi.org/10.3389/fimmu.2022.1022598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727402/
https://www.ncbi.nlm.nih.gov/pubmed/36505399
http://dx.doi.org/10.3389/fimmu.2022.1022598

Ejemplares similares